Related Experiment Video

Updated: Jun 13, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Pertuzumab for the treatment of ovarian cancer

Simon P Langdon1, Dana Faratian, Yoko Nagumo

  • 1Division of Pathology, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK. simon.langdon@ed.ac.uk

Expert Opinion on Biological Therapy
|May 15, 2010
PubMed
Abstract

Insights

Pertuzumab shows promise in treating ovarian cancer by enhancing chemotherapy. Further biomarker-guided trials are needed to confirm its value in HER2-positive patients.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular targeted therapy

Background:

  • Pertuzumab is a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2).
  • It inhibits HER2 heterodimerization and has shown activity in breast and ovarian cancers.
  • Pertuzumab is the most studied HER2 inhibitor in ovarian cancer.

Purpose of the Study:

  • To review preclinical and clinical activity of pertuzumab in ovarian cancer.
  • To identify biomarkers associated with response to pertuzumab.
  • To compare pertuzumab with other HER2 inhibitors in ovarian cancer.

Main Methods:

  • Review of published preclinical and clinical studies on pertuzumab in ovarian cancer.
  • Analysis of clinical trial data and associated preclinical research.
  • Comparison of pertuzumab's efficacy with other HER2 inhibitors.

Main Results:

  • Pertuzumab has been evaluated in nearly 400 patients across three Phase II studies.
  • Pertuzumab enhances gemcitabine in platinum-resistant ovarian cancer and carboplatin in platinum-sensitive disease.
  • Beneficial response observed in patients with activated HER2 or low HER3 mRNA expression.

Conclusions:

  • Pertuzumab demonstrates potential therapeutic value in ovarian cancer treatment.
  • Further prospective, biomarker-driven clinical trials are essential.
  • Biomarker selection may optimize pertuzumab's efficacy in ovarian cancer.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...